Pending 510(k), not available for sale within the United States.
ABOUT
Building with passion and ingenuity.
TendoNova Corporation’s mission is to enhance clinical outcomes for patients with chronic tendon pain by delivering cutting-edge micro-invasive technology that is customizable to individual patient needs without overwhelming expense.
MANAGEMENT TEAM
Mark A Samuels
CEO
Over 30 years of experience in Medical Device, recent successful exit and prior IPO. Inventor on over 25 patents.
Jason Wandersee
CFO
Executive and leader with specialty in corporate growth strategy and building high-performing teams. Previously served leadership roles as board member, CAO, COO, CEO.
Shaun Oveson
VP Sales and Marketing
Sales executive with a proven history of success and achievement in medical devices including 15 years of experience at Arthrex and Stryker prior.
MEDICAL ADVISORS
Kenneth Mautner
M.D.
Gerard Malanga
M.D.
Meagan Jennings
M.D.
Rahul Desai
M.D.
Dr. Mautner is the Assistant Professor in the Department of Physical Medicine and Rehabilitation and the Department of Orthopaedic Surgery at Emory University. He is also the Director of Primary Care Sports Medicine and Fellowship Director at Primary Care Sports Medicine Fellowship. Dr. Mautner is a co-editor of the Atlas of Interventional Musculoskeletal Ultrasound and Musculoskeletal Physical Examination: An Evidence Based Physical Approach. Dr. Mautner is considered a leader in the field of orthobiologics treatment for chronic soft tissue and joint disorders including Platelet Rich Plasma (PRP) and stem cell injections.
Dr. Malanga is the Founder and Partner of New Jersey Sports Medicine, LLC and New Jersey Regenerative Institute in Cedar Knolls, New Jersey. He is board certified in physical medicine and rehabilitation, sports medicine and pain medication. Dr. Malanga is trained in nonoperative treatment of a variety of orthopedic disorders including neck and back pain, as well as shoulder, knee, and other sports medicine and musculoskeletal problems. Dr. Malanga’s expertise includes EMG testing, spinal and joint injections, musculoskeletal ultrasound and PRP, bone marrow and adipose-derived stem cell treatments.
Dr. Jennings is the Director of Silicon Valley Foot & Ankle Reconstructive Fellowship at Palo Alto Medical Foundation. She is a board-certified foot and ankle surgeon with a focus on trauma, reconstruction, and sports medicine at Palo Alto Medical Foundation. Dr. Jennings’s expertise includes Achilles tendon, biomechanics, bunions, diabetic limb salvage, endoscopic plantar fascia surgery, foot surgery, heel surgery, and sports medicine.
Dr. Desai is the founder of RestorePDX, specializing in musculoskeletal radiology and interventional joint and spine medicine. He currently sits on the Board of Directors for the Interventional Orthopedics Foundation. Dr. Desai has expanded his musculoskeletal imaging background (MSK ultrasound, diagnostic MRI, CT, X-ray, interventional fluoroscopy) in combination with PRP, stem cells, and regenerative medicine.
BOARD OF DIRECTORS
Lou Malice
Medical Device Executive with 30+ years of experience in commercialization, R&D, manufacturing, supply chain, and regulatory. Veteran of start-up & growth stage medical device companies.
Peter Haaland
Medical Device Executive with 30+ years of experience in commercialization, R&D, manufacturing, supply chain, and regulatory. Veteran of start-up & growth stage medical device companies.
CO-FOUNDERS
Brett Rogers
Shawna Khouri
Luka Grujic
Jonathan Shaw
DPT, OCS
THE PROBLEM
Tendinopathy is an injury that has failed to heal and is one of the most common causes of pain in the world.
- 30 million Americans have chronic tendon pain (lasting over 3 months).
- Five commonly affected tendon areas include: jumper’s knee, tennis elbow, golf elbow, plantar fasciitis, Achilles tendinopathy, and other tendons.
- 9 million Americans fail to respond to conservative treatment.
- Approximately $1.4 billion of the market is currently unmet.
CURRENT APPROACHES
(Suboptimal for symptom reduction)
-
Conservative Treatment
-
Percutaneous Tenotomy
-
Open Surgery
TM
THE OCELOT SYSTEM
A microinvasive technology designed to perform percutaneous tenotomy under ultrasound-guidance in-office
Pending 510(k), not available for sale within the United States.
1
2
3
4
HOW IT WORKS
Stimulation
Ocelot System mechanically debrides pathological tendon and removes excess ECM to allow for a new healing cycle.
Activation
Pro inflammatory markers (e.g macrophages, neutrophils, and cytokines) activate to start upregulation.
Upregulation
Proteins and growth factors (e.g. IG-F1, TGFβ, PDGF, bFGF, Interleukin) start expressing in the area.
Healing
Tendon repairs and remodels itself to a new healthy state.
FEATURES AND BENEFITS
Improved
Clinical Outcomes
-
Through standardized objective measurements we improve both novice and expert clinician’s outcomes
-
Less expensive and invasive than alternative procedures that need to be done in the OR or Ambulatory Surgical Suite
-
Reduced time and cost: only requires an office visit vs. ASC
-
Increased comfort: more precise than existing tools
-
Requires less movement in the body
Improved Physician Experience
-
Wireless, with little set up time
-
Objective measurements on which to base and defend clinical decisions
-
Economical without sacrificing results
Improved
Patient Experience
Decreased
Cost of Care
Find a Doctor
TendoNova can help you
find an Ocelot System Doctor!
Fill out a request here:
Coming Soon. Stay tuned for updates.
RECOGNITION
CONTACT US
Thank you for your interest in TendoNova Corporation.
Our corporate office’s address and information are listed below:
TendoNova Corporation
1-877-203-0161
3050 Business Park Dr. • Suite A-2 • Norcross, GA 30071
E: info@tendonova.com
INVESTORS
Please email mark.samuels@tendonova.com
regarding investor inquiries.